ストックスクリーナーアプリを入手
4.7165
1.61%
0.0565
Cytek Biosciences Inc (CTKB) 最新ニュース
Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions - Kalkine Media
Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026 - Kalkine Media
Cytek Biosciences (CTKB) CEO gets 120K shares, surrenders some for taxes - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares - Stock Titan
Cytek Biosciences (CTKB) director now holds 28,499 shares - Stock Titan
Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes - Stock Titan
Cytek (CTKB) Quarterly Figures: EPS Prints Above Forecast in the Latest Session; Stock Move: Shares Finish 0.96% HigherEstimate Dispersion - Vinanet
Cytek Biosciences Balances Growth With Profit Pressures - TipRanks
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary - TradingView
Cytek Biosciences Q2 revenue slightly misses estimates - TradingView
Cytek Biosciences Q2 2026: Revenue $48.1M, Gross Profit $28.3M, Net Loss $12.2M - TradingView
Cytek Biosciences, Inc. Raising Revenue Guidance for the Full Year 2026 - marketscreener.com
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million - Bitget
Cytek Biosciences (CTKB) Dips 2.3% to $4.18 as Support at $3.97 Comes into FocusTRIN Signal - dars.gov.et
Cytek Biosciences incentivizes larger reagent purchases with free summer gifts - Traders Union
Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences - stocktitan.net
Cytek Biosciences, Inc. expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cytek Biosciences (CTKB) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Cytek Biosciences, Inc. Revenue Breakdown – TRADEGATE:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Cash Flow - TradingKey
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences Inc (CTKB) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
CTKB|Cytek Biosciences Inc|Price:4.420|Chg%:-0.040 - TradingKey
Cytek Biosciences, Inc. Revenue Breakdown – FWB:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences CTKB Q1 2026 Earnings EPS Misses Estimates by Wide Margin Shares SlipMarket Intelligence - po-news-eg.net
Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making - Traders Union
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
CTKB stock rises as Cytek BioSciences reports revenue and margin trends - Ad-hoc-news.de
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Cytek Biosciences to report Q2 2026 results on August 5 - scanx.trade
Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5 - Stock Titan
Cytek Biosciences reveals special summer incentive for reagent customers - Traders Union
Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus - Ad-hoc-news.de
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - BioSpace
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - Finviz
1.36%
0.01%
大文字化:
|
ボリューム (24 時間):